81 stories found
Goldman Sachs has updated its September investment outlook, incorporating Vertex Pharmaceuticals, RWE, and Adyen into its highest-conviction equity portfolio based on strong growth projections.
Global renewable energy firm Trinasolar has delivered a 10MWh solar and storage project in Phu Quoc, Vietnam, utilizing its Vertex N 725W panels to boost local clean energy capacity.
The potential for AbCellera Biologics (ABCL)'s deal with Vertex Pharmaceuticals Incorporated (VRTX) to transform its TCE platform into a breakthrough is being examined.
Analysts have offered their insights and ratings on healthcare companies Vertex Pharmaceuticals (VRTX) and Q32 Bio (QTTB).
Several companies, including NuScale Power, Cadre Holdings, and NiSource, have released their Q2 2026 earnings previews. Superior Group of Companies, Inc. also provided a summary of its Q2 2026 earnings call.
Vertex Minerals has reported the successful first production firing at its Reward Gold Mine.
Vertex Pharmaceuticals was the sole bidder in the acquisition of Crinetics Pharmaceuticals, securing the deal with a high-premium offer.
A preview details expectations for Vertex Pharmaceuticals' next quarterly earnings report.
Vertex Pharmaceuticals is identified as one of the best QQQ stocks to consider for investment, based on recent market assessments.
Vertex Pharmaceuticals has signed an agreement to acquire Crinetics Pharmaceuticals for $10 billion, marking another significant merger in the pharmaceutical industry. This acquisition is set to expand Vertex's portfolio.
Vertex Pharmaceuticals has announced its acquisition of Crinetics Pharmaceuticals in a deal valued at $10 billion. This marks Vertex's largest acquisition to date, expanding its portfolio in the pharmaceutical sector.
An analysis compares Dyne Therapeutics and Vertex Pharmaceuticals to determine which drug innovator stock presents a better investment opportunity for 2026.
An evaluation compares Kyverna Therapeutics and Vertex Pharmaceuticals to assess which drug developer stock presents a better buying opportunity for 2026.
This article examines whether Vertex Pharmaceuticals stock (VRTX) is underperforming compared to the broader healthcare sector.
A judge has identified Zapatero as the "vertex" and "strategic leader" of a corruption scheme. His indictment was reportedly delayed by six days to avoid interfering with the Andalusian elections.
Several companies, including Root, Adient, TaskUs, and Maximus, have released their earnings call transcripts or summaries for the first or second quarter of 2026. These reports provide financial updates and insights into their recent performance.
Vertex Pharmaceuticals exceeded profit estimates, driven by a significant surge in sales of its new cystic fibrosis drug. The strong performance highlights the drug's market success.
Conestoga Capital Advisors has exited its position in Vertex, stating that the company's valuation no longer reflects a favorable risk-reward profile for their investment strategy.
Google is rebranding and expanding its AI offerings, including Vertex AI, under the new 'Gemini Enterprise' umbrella to enhance its enterprise money-making strategy.
AITX has released its preliminary financial results for fiscal year 2026, showcasing significant revenue growth and an expansion in gross profit.
Vertex Pharmaceuticals has entered into a partnership with Halozyme Therapeutics to utilize its Hypercon drug delivery technology, aiming to enhance pharmaceutical administration.
Vertex (VERX) shares have declined to a 52-week low, attributed to broader AI-related headwinds impacting the software sector and investor sentiment.
Wells Fargo has increased its price target for Vertex Pharmaceuticals (VRTX) to $550, signaling a positive outlook for the biotechnology company.
Vertex Resource has announced its financial results, reporting a GAAP EPS of -C$0.06 and revenues totaling C$54.83 million.
Vertex Pharmaceuticals said its drug for a rare kidney condition succeeded in a Phase 3 trial.
Several financial firms have issued new ratings, price targets, or coverage initiations for biotech and pharmaceutical companies including Beam Therapeutics, Krystal Biotech, 4D Molecular Therapeutics, BioMarin Pharmaceutical, Vertex Pharmaceuticals, CRISPR Therapeutics AG, Regeneron Pharmaceuticals, and UniQure.
An article explores the potential for Vertex stock to turn a $100,000 investment into $1 million by 2036, analyzing its growth prospects.
Vertex Pharmaceuticals has named Jonathan Poole as its new finance chief, coinciding with the closing of Crinetics Pharmaceuticals' acquisition. The executive appointment aligns with broader corporate restructuring efforts.
Vertex Resource Group Ltd. announced its financial results, reporting a GAAP EPS of $0.01 and revenue totaling $51.23 million.
Vertex Pharmaceuticals' stock has rallied after Sionna Therapeutics' experimental cystic fibrosis drug failed in clinical trials. This outcome highlights the competitive landscape in drug development, where one company's setback can benefit another.
Defender has expanded its model range by introducing the new 'Vertex,' featuring updated exterior design solutions, advanced technologies, and engine choices. The 'Defender 110' will also be offered for the first time as a six-seater model.
Key highlights from Vertex Pharmaceuticals' second-quarter earnings call were released, providing insights into the company's financial performance and future outlook.
Vertex has completed a $10 billion acquisition of Crinetics, leading to speculation that Viking Therapeutics could be the next major pharmaceutical company to be targeted for a takeover.
Vertex Pharmaceuticals has announced its intention to acquire Crinetics Pharmaceuticals in an all-cash deal valued at $85 per share.
This article highlights notable healthcare headlines for the week, focusing on companies like UnitedHealth, Vertex, and CVS Health.
Land Rover has updated its popular Defender SUV with a new Vertex version, featuring a more aggressive design and practical additions for off-road enthusiasts.
Vertex Pharmaceuticals has announced its intention to acquire Crinetics Pharmaceuticals in a deal valued at $10 billion, marking a significant expansion into endocrine disease drugs.
TD Cowen has given Vertex (VERX) a 'Buy' rating, noting an improvement in market sentiment driven by the company's execution.
An analysis compares CRISPR Therapeutics AG and Vertex Pharmaceuticals to determine which healthcare stock presents a better investment opportunity for 2026. The evaluation focuses on their respective market positions and future prospects.
An analyst report has been released providing insights and analysis on Vertex Pharmaceuticals Inc.
Vertex Pharmaceuticals (VRTX) announced that Health Canada has accepted its New Drug Submission (NDS) for Suzetrigine, moving the potential treatment closer to market approval in Canada.
A range of companies, including Allarity Therapeutics, Beam Global, and Boot Barn, have released their latest quarterly financial results. These reports detail GAAP EPS, revenue figures, and often include earnings call transcripts or highlights.
UniCredit Bank has announced a record quarterly profit, with its net profit in Czechia and Slovakia also seeing a significant increase. This financial performance highlights strong investment income for the banking group.
The Zacks Analyst Blog has published several posts highlighting various companies across different sectors. These analyses cover firms such as Cullen/Frost Bankers, Sonic Automotive, Moderna, Merck, Apple, Amazon, and Starbucks.
Analysts have provided their latest insights and ratings on technology companies Vertex (VERX) and ViaSat (VSAT), offering perspectives on their market performance and future outlook.
Financial commentator Jim Cramer shared his sentiment on Vertex Pharmaceuticals, stating he wished he had purchased the stock for his Charitable Trust much earlier.
Morgan Stanley has increased its price target for Vertex Pharmaceuticals to $612 from $596, indicating a positive outlook for the company's stock.
ORIC Pharmaceuticals experienced a drop in its stock value after releasing early-stage trial data for its prostate cancer therapy. The market reacted negatively to the initial results of the clinical study.
Vertex (VERX) has announced the launch of its new tax engine and indirect tax accelerator, making these solutions available on the Oracle Marketplace.
An article provides an analysis on whether Vertex Pharmaceuticals Incorporated (VRTX) is currently a favorable stock for investment.
Vertex Pharmaceuticals stock is rising following the release of positive interim data from its Phase 3 clinical trial for IgAN.
An article evaluates whether Vertex stock is currently outperforming the Dow Jones Industrial Average, providing insights into its market performance.
Vertex is highlighted as a stable biotech compounder, recommended for long-term holding even through market downturns.
Vertex Pharmaceuticals has expanded its senior management roster with three new appointments aimed at strengthening corporate governance and strategic direction.
Reports analyze whether Wall Street analysts maintain a bullish sentiment regarding Vertex Pharmaceuticals stock, providing insights into their current evaluations.
The new Defender Vertex model has been unveiled, building on the iconic 4x4's character with a more dynamic design, enhanced customization options, and new technologies.
Vertex Pharmaceuticals stock experienced an increase on Tuesday, with the article exploring the potential reasons behind the positive market movement.
Vertex Pharmaceuticals has increased its annual revenue forecast, attributing the positive outlook to the strong performance of its cystic fibrosis drugs.
AbCellera has signed a drug discovery agreement with Vertex Pharmaceuticals, focusing on developing new therapeutic solutions.
An analysis explains why Vertex Pharmaceuticals was willing to pay a premium of more than 100% to acquire Crinetics Pharmaceuticals.
Vertex Pharmaceuticals is making a significant $10 billion investment in Crinetics, aiming to establish a leading position in the endocrinology sector.
A Yahoo Finance article discusses Vertex's deal with Crinetics, analyzing how the acquisition balances potential growth opportunities with inherent integration risks.
Vertex Pharmaceuticals has announced its intention to acquire Crinetics Pharmaceuticals for $10 billion, a move aimed at expanding its business in the rare-disease treatment sector.
Vertex Pharmaceuticals announced that its gene therapy, Casgevy, has received an expanded indication, allowing its use in children as young as two years old.
Recent analyses evaluate whether various companies, including Expedia Group (EXPE), Domino’s Pizza (DPZ), Donnelley Financial Solutions (DFIN), DoorDash (DASH), Vertex Pharmaceuticals (VRTX), Stevanato Group (STVN), Ondas Inc. (ONDS), The Wendy’s Company (WEN), Five Below (FIVE), and VNET Group (VNET), are good stocks to buy. These reports assess the investment viability of each company.
The earnings transcript for Vertex (VERX) for the first quarter of 2026 has been released. This document provides detailed insights into the company's financial performance and operational highlights for the period.
Wall Street analysts have provided their target price assessments for Vertex Pharmaceuticals stock, indicating their expectations for its future performance.
Analysts are preparing for the upcoming Q1 2026 earnings report from Bakkt Holdings and the Q2 2026 earnings report from Vertex Pharmaceuticals. These previews offer insights into expected financial performance for both companies.
This article provides a summary of Vertex Pharmaceuticals Incorporated's first-quarter 2026 earnings call.
Bank of America (BofA) has named Vertex (VRTX) as its top biotech pick for the year 2026.
RBC Capital Markets has increased its price target for Vertex Pharmaceuticals (VRTX) as it updates its outlook for the biotech sector. This reflects a positive analyst sentiment towards the company.
Morgan Stanley has increased its price target for Vertex Pharmaceuticals (VRTX) following updates to its biopharma models.
A preview of Vertex Pharmaceuticals' first-quarter 2026 earnings report outlines what investors and analysts can anticipate regarding the company's financial results and future outlook.
Vertex Pharmaceuticals has announced the completion of its rolling Biologics License Application (BLA) submission for povetacicept.
Vertex Pharmaceuticals has applied for refund approval for its latest drug, a new targeted therapy for specific genetic subtypes of cystic fibrosis, in Poland. The company continues to seek therapies for the condition.
Truist has increased its price target for Vertex Pharmaceuticals (VRTX) following the announcement of positive Phase 3 trial results.
These are the stocks posting the largest moves in early trading.
Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy TradingView
Analyst confidence in Vertex is strong following the company's positive fourth-quarter results.
This article examines whether Wall Street analysts are bullish or bearish on Vertex Pharmaceuticals stock.